BSE filing, NSE: NOVARTIND. Summary written from the filing by ALFA Finder's alert engine.
Novartis India Ltd: key numbers
- Share price
- ₹1,762.40
- Market cap
- ₹4,352 Cr
- Revenue (annual)
- ₹354.3 Cr
- Net profit (annual)
- ₹93.18 Cr
- P/E (TTM)
- -1090.6×Sector 43.0×
- Promoter holding
- 70.68%+0.00% QoQ
- FII holding
- 1.21%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Novartis India Ltd
All →Evonile Pharma Fund Raise of ₹900 Cr
Evonile Pharma's board approved a partly paid rights issue of up to Rs 900 Crore. A committee will set the issue price, record date and entitlement.
- Value
- ₹900.0 Cr
Evonile Pharma Capital Structure Change
Evonile Pharma's Rights Issue Committee fixed November 11, 2026 as record date for a partly paid rights issue of 1,02,87,832 shares at Rs.860 each. Issue size is Rs.8,847.54 Million, with issue opening November 19, 2026.
- Value
- ₹884.8 Cr
- Execution
- Issue opening 19 Nov 2026 to closing 3 Dec 2026; listing on or about 9 Dec 2026
Evonile Pharma Earnings Call Transcript: Key Takeaways
Q2 FY27 revenue ₹56.1 cr (-38% YoY) and PAT loss ₹77.5 cr, including ₹68 cr exceptional items. H1 revenue ₹159.9 cr (-10%). Transitioning to an independent branded pharma model; Minipress XL acquired.
Evonile Pharma Results Update
Evonile Pharma reported Q2 FY27 revenue of ₹56.1 crore and an EBITDA loss of ₹31.8 crore. H1 FY27 profit after tax was a loss of ₹45.3 crore.
Evonile Pharma Investor Presentation: Key Takeaways
Q2 FY27 revenue fell 38% YoY to ₹56.1 cr, with a ₹77.5 cr net loss including ₹68 cr exceptional items. Transition from single-customer model to independent distribution continues.
Evonile Pharma Q2 FY27 Results: Net Loss of ₹77.5 Cr
Evonile Pharma posted a ₹775.4 million quarterly loss for September 2026 versus profit a quarter earlier. Exceptional items of ₹682.6 million drove the half-year pre-tax loss.
- Key figure
- Net loss ₹77.5 Cr
Other promoter reclassification announcements
All →Baba Arts Promoter Reclassification
Baba Arts' board noted promoters Gordhan and Rahul Tanwani's request to reclassify as public shareholders. Company Secretary Naishadh Mankad resigned and Shilpi Shukla was appointed.
Vaxtex Cotfab Promoter Reclassification
Vaxtex Cotfab received NSE approval to reclassify Bharti Kailash Gupta, holding 0.40%, from promoter group to public. The change took effect on 5 November 2026.
Shri Gang Industries and Allied Products Promoter Reclassification
Shri Gang Industries received BSE no-objection for reclassifying four Gupta family members from promoter to public category under Regulation 31A. Shareholder approval is still required, and no monetary value is involved.
Olympic Management & Financial Services Promoter Reclassification
Olympic Management & Financial Services received BSE no-objection to reclassify Excel Paints Private Limited from promoter to public category under Regulation 31A. No shares or money changed hands.
EMA India Promoter Reclassification
EMA India submitted minutes of a postal ballot completed on 8 October 2026. Members approved reclassifying 38,000 shares (3.78%) from promoter to public category under Regulation 31A.
GSPL Transmission Promoter Reclassification
GSPL Transmission's board approved GSEG's request to reclassify from Promoter to Public shareholder, subject to Regulation 31A approvals. No shareholder approval is needed as GSEG holds under 1% of voting rights.